Clinical Trials Logo

Filter by:
NCT ID: NCT00861679 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International

ALL SCT BFM
Start date: January 2007
Phase: N/A
Study type: Interventional

To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). To evaluate the efficacy of HSCT from mismatched family or unrelated donors (MMD) as compared to HSCT from MSD/MD. To determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. To prospectively evaluate and compare the incidence of acute and chronic GvHD after HSCT from MSD, from MD and from MMD.

NCT ID: NCT00861614 Completed - Prostate Cancer Clinical Trials

Study of Immunotherapy to Treat Advanced Prostate Cancer

Start date: May 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine if advanced prostate cancer patient s that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone

NCT ID: NCT00861523 Terminated - Clinical trials for Hyperemesis Gravidarum

Does Thiamine Help Vomiting and Nausea in Pregnancy?

Start date: February 2009
Phase: Phase 3
Study type: Interventional

There are different treatments for nausea and vomiting in pregnancy. According to the ACOG recommendations, promethazine is the first line of parenteral treatment after oral treatment had failed. Thiamine is given to prevent wernicke encephalopathy. This research try to find out whether thiamine helps the vomiting and nausea as well, by comparing the response to thiamine and promethazine in women who suffer from nausea and vomiting in pregnancy.

NCT ID: NCT00860288 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Start date: February 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin

NCT ID: NCT00859664 Recruiting - Autism Clinical Trials

Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders

Start date: March 2009
Phase: N/A
Study type: Observational

Children with autism are often treated with psychiatric drugs. These medications have been shown to improve their language and social function, and are important in improving their quality of life. In many cases it is difficult to determine the best drug dose, and a favorable response occurs in only 30%-70% of individuals, with many children suffering significant adverse drug reactions. Pharmacogenetics is the study of the role of different genes on drug behavior. The cytochrome P450 is the most important enzyme, involved in the metabolism of a vast number of drugs, including psychiatric medications. The multiple variations in this gene can result in the different response observed in different patients, even when treated with similar doses of the drug. Hypothesis(es): Mapping the different types of cytochrome P450 gene, in children with autistic disorders will improve the rate of success of medical treatment, and prevent adverse drug reactions. Potential Impact: If successful, our study can help thousands of children and their families by developing a system of "tailored medicine" that is based on the specific activity of the various enzymes present in that particular patient. Better medical treatment will facilitate better daily interactions with the children and enhance their quality of life. Furthermore, recognizing children that are resistant to medication will prevent unnecessary use of drugs. It should be noted this is the first study focusing on children receiving psychiatric medications using pharmacogenetics. Found to be effective, this method can also be applied to other groups of medications and to other patients.

NCT ID: NCT00859365 Completed - Anxiety Clinical Trials

Acupuncture for Back and Neck Pain in an Emergency Room Setting

ABNP
Start date: January 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to examine the efficacy of an Integrative approach utilizing Acupuncture as an add-on therapy for the treatment back and neck pain in an emergency department setting Acupuncture is well established as an effective treatment for back pain. The investigators cumulative experience in Asaf Harofeh Medical Center has shown Acupuncture to be an Effective therapy for simple back and neck pain in an ER setting. This study will examine weather Acupuncture can decrease pain, increase range of motion and decrease anxiety in patients admitted to the Emergency Room with simple back and neck pain without neurological findings. Acupuncture will be performed as an add on therapy on top of analgesic therapy.

NCT ID: NCT00859209 Completed - Clinical trials for Infants in NICU Ventilated With HFV

Capnography in Infants Ventilated With High Frequency Ventilation

Start date: December 2008
Phase: N/A
Study type: Observational

The investigators hypothesize that dEtCO2 measured by the Microstream® technique via a double-lumen ETT in infants ventilated with HFV would be feasible and adequately represent the arterial CO2 (PaCO2).

NCT ID: NCT00858637 Completed - Clinical trials for Chronic Kidney Disease

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Start date: March 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney disease Stage V on dialysis. This study incorporates a Washout Period and two treatment periods - an active comparison phase and a placebo-controlled withdrawal phase.

NCT ID: NCT00858546 Completed - Parkinson's Disease Clinical Trials

The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease

Start date: May 2009
Phase: N/A
Study type: Interventional

The aim of the study is to test the effects of low frequency deep rTMS using the novel H-coil on the motor, affective and cognitive deficits in patients with Parkinson's disease (PD) and to establish its safety in this population. The investigators anticipate to recruit 10 patients to an open pilot study. All patients will receive an active rTMS stimulation and will be given 12 treatment sessions, over a period of up to 4 weeks. Each of the 12 daily treatment sessions (lasting about 30 minutes each), will be consisted of 25 stimulation trains over the prefrontal cortex (20Hz trains, 2 seconds each with an inter-train interval of 20 seconds) and one train of 15 minutes at 1 Hz over the the motor cortex. The following outcome measures will be taken prior to the treatment (screening visit), and at day 1, 10, 30, 60, and 90: 1. Unified Parkinson's Disease Rating Scale (UPDRS ) 2. Clinical Global Impression of Severity (CGIS) 3. Pegboard test. 4. Tapping test 5. Up & Go test 6. Abnormal Involuntary Movement Scale (AIMS) Mood and affect Beck Depression Inventory (BDI) Cognition 1. Mini mental State examination (MMSE) 2. Digit forward and backward tests. 3. Word fluency. 4. Frontal Assessment Battery (FAB) Side effects will be closely monitored by the researchers and will be promptly reported to the IRB

NCT ID: NCT00858364 Terminated - Cancer Clinical Trials

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Start date: July 17, 2009
Phase: Phase 3
Study type: Interventional

This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL compared to participants treated with placebo.